• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

假尿苷修饰酶与癌症的进展

Advancements in pseudouridine modifying enzyme and cancer.

作者信息

Liu Kaijie, Zhang Shujun, Liu Yafeng, Hu Xinjun, Gu Xinyu

机构信息

Department of Infectious Diseases, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, Henan, China.

Henan Medical Key Laboratory of Gastrointestinal Microecology and Hepatology, Luoyang, China.

出版信息

Front Cell Dev Biol. 2024 Dec 16;12:1465546. doi: 10.3389/fcell.2024.1465546. eCollection 2024.

DOI:10.3389/fcell.2024.1465546
PMID:39737343
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11683142/
Abstract

Pseudouridine (Ψ) is a post-transcriptional modifier of RNA, often referred to as the 'fifth nucleotide' owing to its regulatory role in various biological functions as well as because of its significant involvement in the pathogenesis of human cancer. In recent years, research has revealed various Ψ modifications in different RNA types, including messenger RNA, transfer RNA, ribosomal RNA, small nuclear RNA, and long noncoding RNA. Pseudouridylation can significantly alter RNA structure and thermodynamic stability, as the Ψ-adenine (A) base pair is more stable than the typical uridine (U)-A base pair is due to its structural similarity to adenine. Studies have linked Ψ expression to the development and progression of several digestive system cancers, such as liver cancer and colorectal cancer, and nondigestive system cancers, such as breast cancer, non-small cell lung cancer, prostate cancer, glioblastoma, ovarian cancer, oral squamous cell carcinoma, and pituitary cancer. The present review briefly outlines the chemical structure, synthesis, and regulatory mechanisms of Ψ. This review summarizes the effects of pseudouridylation on various substrates of RNA and briefly discusses methods for detecting Ψ. Last, it focuses on how RNA pseudouridylation influences different cancers, emphasizing the search for novel approaches to cancer diagnosis, treatment, and prognosis through Ψ modification.

摘要

假尿苷(Ψ)是RNA的一种转录后修饰物,由于其在多种生物学功能中的调节作用以及在人类癌症发病机制中的重要参与,常被称为“第五种核苷酸”。近年来,研究揭示了不同RNA类型中的各种Ψ修饰,包括信使RNA、转运RNA、核糖体RNA、小核RNA和长链非编码RNA。假尿苷化可显著改变RNA结构和热力学稳定性,因为Ψ-腺嘌呤(A)碱基对比典型的尿苷(U)-A碱基对更稳定,这是由于其与腺嘌呤的结构相似性。研究已将Ψ的表达与几种消化系统癌症(如肝癌和结直肠癌)以及非消化系统癌症(如乳腺癌、非小细胞肺癌、前列腺癌、胶质母细胞瘤、卵巢癌、口腔鳞状细胞癌和垂体癌)的发生和发展联系起来。本综述简要概述了Ψ的化学结构、合成及调控机制。本综述总结了假尿苷化对RNA各种底物的影响,并简要讨论了检测Ψ的方法。最后,重点阐述了RNA假尿苷化如何影响不同癌症,强调通过Ψ修饰寻找癌症诊断、治疗和预后的新方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48f9/11683142/15817ca5e88a/fcell-12-1465546-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48f9/11683142/83cf5232747b/fcell-12-1465546-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48f9/11683142/9de90a306764/fcell-12-1465546-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48f9/11683142/15817ca5e88a/fcell-12-1465546-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48f9/11683142/83cf5232747b/fcell-12-1465546-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48f9/11683142/9de90a306764/fcell-12-1465546-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/48f9/11683142/15817ca5e88a/fcell-12-1465546-g003.jpg

相似文献

1
Advancements in pseudouridine modifying enzyme and cancer.假尿苷修饰酶与癌症的进展
Front Cell Dev Biol. 2024 Dec 16;12:1465546. doi: 10.3389/fcell.2024.1465546. eCollection 2024.
2
Decoding the 'Fifth' Nucleotide: Impact of RNA Pseudouridylation on Gene Expression and Human Disease.解码“第五个”核苷酸:RNA 假尿嘧啶化对基因表达和人类疾病的影响。
Mol Biotechnol. 2024 Jul;66(7):1581-1598. doi: 10.1007/s12033-023-00792-1. Epub 2023 Jun 21.
3
Implications of RNA pseudouridylation for cancer biology and therapeutics: a narrative review.RNA 假尿嘧啶化对癌症生物学和治疗学的影响:叙述性综述。
J Transl Med. 2024 Oct 7;22(1):906. doi: 10.1186/s12967-024-05687-6.
4
Pseudouridylation meets next-generation sequencing.假尿苷化与新一代测序技术相遇。
Methods. 2016 Sep 1;107:63-72. doi: 10.1016/j.ymeth.2016.03.001. Epub 2016 Mar 8.
5
RNA-guided isomerization of uridine to pseudouridine--pseudouridylation.RNA引导的尿苷异构化为假尿苷——假尿苷化
RNA Biol. 2014;11(12):1483-94. doi: 10.4161/15476286.2014.972855.
6
Transcriptome-wide mapping of pseudouridines: pseudouridine synthases modify specific mRNAs in S. cerevisiae.假尿苷的全转录组图谱:假尿苷合酶修饰酿酒酵母中的特定mRNA。
PLoS One. 2014 Oct 29;9(10):e110799. doi: 10.1371/journal.pone.0110799. eCollection 2014.
7
Thermodynamic contribution and nearest-neighbor parameters of pseudouridine-adenosine base pairs in oligoribonucleotides.寡核糖核苷酸中假尿嘧啶-腺嘌呤碱基对的热力学贡献和最近邻参数。
RNA. 2013 Nov;19(11):1474-82. doi: 10.1261/rna.039610.113. Epub 2013 Sep 23.
8
Pseudouridine in RNA: what, where, how, and why.RNA中的假尿苷:是什么、在哪里、如何以及为何存在。
IUBMB Life. 2000 May;49(5):341-51. doi: 10.1080/152165400410182.
9
Posttranscriptional RNA Pseudouridylation.转录后RNA假尿苷化
Enzymes. 2017;41:151-167. doi: 10.1016/bs.enz.2017.02.001. Epub 2017 Mar 11.
10
Post-transcriptional pseudouridylation in mRNA as well as in some major types of noncoding RNAs.mRNA 以及一些主要类型的非编码 RNA 中的转录后假尿嘧啶化。
Biochim Biophys Acta Gene Regul Mech. 2019 Mar;1862(3):230-239. doi: 10.1016/j.bbagrm.2018.11.002. Epub 2018 Nov 8.

引用本文的文献

1
Analysis of the mRNA modification machinery alterations in breast cancer through the SCAN-B cohort.通过SCAN-B队列分析乳腺癌中mRNA修饰机制的改变。
NAR Cancer. 2025 Sep 3;7(3):zcaf027. doi: 10.1093/narcan/zcaf027. eCollection 2025 Sep.
2
Epitranscriptomic alterations induced by environmental toxins: implications for RNA modifications and disease.环境毒素诱导的表观转录组改变:对RNA修饰和疾病的影响。
Genes Environ. 2025 Aug 4;47(1):14. doi: 10.1186/s41021-025-00337-9.
3
Pseudouridine reprogramming in the human T cell epitranscriptome: from primary to immortalized states.

本文引用的文献

1
MYC Drives mRNA Pseudouridylation to Mitigate Proliferation-Induced Cellular Stress during Cancer Development.MYC驱动mRNA假尿苷化以减轻癌症发展过程中增殖诱导的细胞应激。
Cancer Res. 2024 Dec 2;84(23):4031-4048. doi: 10.1158/0008-5472.CAN-24-1102.
2
PUS7-dependent pseudouridylation of ALKBH3 mRNA inhibits gastric cancer progression.PUS7 依赖性 ALKBH3 mRNA 的假尿嘧啶化抑制胃癌进展。
Clin Transl Med. 2024 Aug;14(8):e1811. doi: 10.1002/ctm2.1811.
3
Pseudouridine Detection and Quantification Using Bisulfite Incorporation Hindered Ligation.
人类T细胞表观转录组中的假尿苷重编程:从原代状态到永生化状态。
RNA. 2025 Jul 9. doi: 10.1261/rna.080633.125.
使用亚硫酸氢盐掺入受阻连接检测和定量假尿嘧啶核苷。
ACS Chem Biol. 2024 Aug 16;19(8):1813-1819. doi: 10.1021/acschembio.4c00387. Epub 2024 Jul 16.
4
Structural basis of pri-let-7 recognition by human pseudouridine synthase TruB1.真核生物假尿嘧啶核苷合成酶 TruB1 识别 pri-let-7 的结构基础
Biochem Biophys Res Commun. 2024 Aug 20;721:150122. doi: 10.1016/j.bbrc.2024.150122. Epub 2024 May 14.
5
New directions for Ψ and mA decoding in mRNA: deciphering the stoichiometry and function.在 mRNA 中 Ψ 和 mA 解码的新方向:破译计量和功能。
RNA. 2024 Apr 16;30(5):537-547. doi: 10.1261/rna.079950.124.
6
Advantages and challenges associated with bisulfite-assisted nanopore direct RNA sequencing for modifications.亚硫酸氢盐辅助纳米孔直接RNA测序用于修饰的优势与挑战。
RSC Chem Biol. 2023 Aug 23;4(11):952-964. doi: 10.1039/d3cb00081h. eCollection 2023 Nov 1.
7
The C-terminal extension of dyskerin is a dyskeratosis congenita mutational hotspot that modulates interaction with telomerase RNA and subcellular localization.端粒酶假尿嘧啶合成酶的C末端延伸是先天性角化不良的突变热点,可调节与端粒酶RNA的相互作用及亚细胞定位。
Hum Mol Genet. 2024 Feb 1;33(4):318-332. doi: 10.1093/hmg/ddad180.
8
Bisulfite and Nanopore Sequencing for Pseudouridine in RNA.亚硫酸氢盐和纳米孔测序用于 RNA 中的假尿嘧啶。
Acc Chem Res. 2023 Oct 3;56(19):2740-2751. doi: 10.1021/acs.accounts.3c00458. Epub 2023 Sep 13.
9
Higher expression of pseudouridine synthase 7 promotes non-small cell lung cancer progression and suggests a poor prognosis.尿嘧啶核苷合成酶 7 表达上调促进非小细胞肺癌进展并提示预后不良。
J Cardiothorac Surg. 2023 Jul 7;18(1):222. doi: 10.1186/s13019-023-02332-z.
10
May Be a Potential Prognostic Biomarker and Therapeutic Target for Hepatocellular Carcinoma.可能是肝细胞癌的一种潜在预后生物标志物和治疗靶点。
Pharmgenomics Pers Med. 2023 Apr 15;16:337-355. doi: 10.2147/PGPM.S405621. eCollection 2023.